Earnings ·
Carlsmed reports Q3 revenue of $21.6M and raises full-year guidance to $78M-$80M
CARLCarlsmed, Inc.
Carlsmed reported third-quarter 2026 revenue of $21.6 million, a 65% increase year-over-year, driven by strong execution in its AI-enabled personalized spine surgery platform. The company raised its full-year 2026 revenue guidance to a range of $78 million to $80 million, representing over 56% growth at the midpoint versus 2025. Gross profit reached $16.7 million with a margin of 77.3%, while operating expenses increased to $29.4 million due to executive transition costs and legal matters. The firm also announced CMS inpatient reimbursement increases for its aprevo lumbar procedure and launched a new bilateral posterior system. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions.